Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
Author:
Affiliation:
1. University of Alabama at Birmingham (UAB) School of Medicine; Birmingham AL USA
2. Mount Sinai Tisch Cancer Institute; New York NY USA
3. Duke Cancer Institute and the Duke Prostate Center; Duke University; Durham NC USA
Funder
Teva Pharmaceuticals (writing assistance)
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12867/fullpdf
Reference101 articles.
1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points;Tannock;J Clin Oncol,1996
2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
4. Abiraterone and increased survival in metastatic prostate cancer;Bono;N Engl J Med,2011
5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Coronaphobia: A barrier to ongoing cancer treatment?;Psycho-Oncology;2022-03-03
2. The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype;PeerJ;2021-02-01
3. How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer;Future Oncology;2020-10
4. Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model;2020-09-16
5. The long non-coding RNAGHSROSreprograms prostate cancer cell lines toward a more aggressive phenotype;2019-06-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3